TR201900057T4 - Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler. - Google Patents

Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler. Download PDF

Info

Publication number
TR201900057T4
TR201900057T4 TR2019/00057T TR201900057T TR201900057T4 TR 201900057 T4 TR201900057 T4 TR 201900057T4 TR 2019/00057 T TR2019/00057 T TR 2019/00057T TR 201900057 T TR201900057 T TR 201900057T TR 201900057 T4 TR201900057 T4 TR 201900057T4
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
new
azaindole derivatives
hdac
histone deacetylase
Prior art date
Application number
TR2019/00057T
Other languages
English (en)
Inventor
Lee Changsik
Yang Hyun-Mo
Lee Changkon
BAE Miseon
Kim Soyoung
Choi Youngil
Ha Nina
Lee Jaekwang
Oh Jungtaek
Song Hyeseung
Kim Ilhyang
Choi Daekyu
Min Jaeki
Lim Hyojin
Bae Daekwon
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of TR201900057T4 publication Critical patent/TR201900057T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Mevcut buluş, yeni azaindol deriveleri ve daha belirgin olarak, histon deasetilaz (HDAC) inhibitör aktivitesine sahip yeni azaindol deriveleri, izomerleri, farmasötik olarak kabul edilebilir tuzları, hidratları veya solvatları, bunların farmasötik bileşimlerin hazırlanışı için kullanımları, bunları içeren farmasötik bileşimler, farmasötik bileşimlerin kullanıldığı hastalık tedavi etme yöntemleri ve yeni azaindol derivelerinin hazırlanmasına yönelik yöntemler ile ilgilidir. Mevcut buluşa göre yeni azaindol deriveleri, selektif histon deasetilaz (HDAC) inhibitörleridir ve habis tümör hastalıkları, inflamatuar hastalıklar, romatoid artrit ve nörodejeneratif hastalıkların tedavisine yönelik ajanlar olarak kullanılabilir.
TR2019/00057T 2013-12-12 2014-12-12 Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler. TR201900057T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20130154455 2013-12-12

Publications (1)

Publication Number Publication Date
TR201900057T4 true TR201900057T4 (tr) 2019-01-21

Family

ID=53370682

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00057T TR201900057T4 (tr) 2013-12-12 2014-12-12 Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler.

Country Status (12)

Country Link
US (1) US9650379B2 (tr)
EP (1) EP3080125B1 (tr)
JP (2) JP2016540024A (tr)
KR (1) KR101689394B1 (tr)
CN (1) CN105940001B (tr)
DK (1) DK3080125T3 (tr)
ES (1) ES2704704T3 (tr)
HR (1) HRP20181965T1 (tr)
PL (1) PL3080125T3 (tr)
PT (1) PT3080125T (tr)
TR (1) TR201900057T4 (tr)
WO (1) WO2015087151A1 (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6726658B2 (ja) * 2014-04-11 2020-07-22 イェン、ユンＹＥＮ，Ｙｕｎ ヒストン脱アセチル化酵素阻害剤
JP6559325B2 (ja) 2015-07-27 2019-08-14 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾールアミド誘導体化合物及びこれを含有する薬剤学的組成物，
RU2697665C1 (ru) 2015-07-27 2019-08-16 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфонамида в качестве ингибиторов деацетилазы гистонов 6 и фармацевтическая композиция, содержащая их
AU2016299486B2 (en) 2015-07-27 2019-08-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
HUE057544T2 (hu) 2015-08-04 2022-05-28 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazol-származék vegyületek mint hiszton deacetiláz 6 inhibitorok, és ezeket tartalmazó gyógyszerkészítmények
US10494355B2 (en) 2015-10-12 2019-12-03 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JP6919977B2 (ja) 2016-03-16 2021-08-18 クラ オンコロジー，インク． メニン−ｍｌｌの置換された阻害剤及びその使用方法
KR102002581B1 (ko) * 2016-10-04 2019-07-22 주식회사 종근당 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
IT201700041723A1 (it) 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
KR102236356B1 (ko) 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
MX2021004125A (es) * 2018-10-12 2021-06-15 Chong Kun Dang Pharmaceutical Corp Composicion farmaceutica que comprende inhibidor de histona desacetilasa y metotrexato.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
CA2703718A1 (en) * 2007-11-02 2009-05-07 Tammy Mallais Inhibitors of histone deacetylase
KR20100094554A (ko) * 2007-12-06 2010-08-26 쉐링 코포레이션 감마 세크레타제 조절인자
KR101168801B1 (ko) 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
US8431538B2 (en) 2009-07-22 2013-04-30 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods of using same
CA2825599C (en) * 2011-02-01 2021-07-13 The Board Of Trustees Of The University Of Illinois 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors
US20150197497A1 (en) * 2011-06-24 2015-07-16 Dana-Farber Cancer Institute, Inc. Selective inhibitors of histone deacetylase isoform 6 and methods thereof
WO2013052110A1 (en) * 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
US20140315889A1 (en) * 2011-10-28 2014-10-23 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
EP2785720B1 (en) 2011-11-29 2017-08-09 Nanjing Allgen Pharma Co. Ltd. Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents

Also Published As

Publication number Publication date
EP3080125B1 (en) 2018-10-10
EP3080125A1 (en) 2016-10-19
EP3080125A4 (en) 2017-08-02
PT3080125T (pt) 2018-12-14
DK3080125T3 (en) 2019-01-07
KR20150068923A (ko) 2015-06-22
PL3080125T3 (pl) 2019-06-28
CN105940001A (zh) 2016-09-14
CN105940001B (zh) 2018-02-06
US9650379B2 (en) 2017-05-16
WO2015087151A1 (en) 2015-06-18
JP6561167B2 (ja) 2019-08-14
JP2016540024A (ja) 2016-12-22
JP2018109068A (ja) 2018-07-12
ES2704704T3 (es) 2019-03-19
KR101689394B1 (ko) 2016-12-23
US20160289230A1 (en) 2016-10-06
HRP20181965T1 (hr) 2019-02-08

Similar Documents

Publication Publication Date Title
TR201900057T4 (tr) Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler.
PH12015502425A1 (en) Novel compounds for selective histone deacetylase inhibitors, and pharmeceutical composition comprising the same
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201792047A1 (ru) Новые соединения
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
GEP20217247B (en) Indole derivatives for use in medicine
EA201591296A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201792028A1 (ru) Альфа-цинамидные соединения и композиции как ингибиторы hdac8
EA201591823A1 (ru) Ингибиторы ido
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201590941A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201490042A1 (ru) Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
GEP20196942B (en) Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors
EA201891526A2 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201690129A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
MX2016014911A (es) Acidos hidroxamicos heterociclicos como inhibidores de proteina desacetilasa e inhibidores dobles de proteina desacetilasa-proteina cinasa, y metodos de uso de los mismos.